Cerevel Therapeutics Is A Clinical Stage Biopharmaceutical Company Dedicated To Developing Therapies For Neurological And Neuropsychiatric Disordersfounded In 2018 Through A Partnership Between Bain Capital And Pfizerthe Company Is Based In The Greater Boston Areacerevel Became Publicly Traded In October 2020 And Is Now Part Of Abbviewhich Enhances Its Ability To Deliver Treatments For Brain Disorders Cerevel S Pipeline Focuses On Central Nervous System Disordersutilizing A Receptor Selectivity Approachthe Company Is Advancing Therapies For Conditions Such As Parkinsonae S Diseaseschizophreniaepilepsyalzheimerae S Diseaseand Substance Use Disorderits Portfolio Includes Five Clinical Stage Therapies And Several Preclinical Candidateswith A Mix Of Small Molecules And Potential Biologicscerevel Collaborates With Researchers And Healthcare Professionals To Further Its Clinical Programsaiming To Meet The Needs Of Patients With Unmet Medical Requirements In Neurology And Psychiatry
